Reply to the letter from Blay et al. Pretreatment serum CRP and response to interleukin 2

Steven D. Heys*, John Broom, Oleg Eremin

*Corresponding author for this work

Research output: Contribution to journalLetter

Abstract

Sir- We read with interest the letter from Blay et al. confirming our initial findings in patients with metastatic colorectal cancer that pretreatment measurement of serum C-reactive protein (CRP) levels could predict which patients with metastatic renal cancer would respond to rIL-2-based therapy. Our preliminary data have also indicated that there are differences in other acute-phase proteins (albumin, transferrin, retinol-binding protein and transferrin) between patients who do or do not respond to rIL-2 treatments. Furthermore, we have also found that these measurements not only predict tumour response (in terms of reduction in tumour volume) but also predict the survival of these patients following treatment.
Original languageEnglish
Number of pages1
JournalBritish Journal of Cancer
Volume69
Issue number1
DOIs
Publication statusPublished - 1 Jan 1994

Fingerprint Dive into the research topics of 'Reply to the letter from Blay et al. Pretreatment serum CRP and response to interleukin 2'. Together they form a unique fingerprint.

  • Cite this